推薦產品
形狀
powder
品質等級
包含
arginine as stabilizer (~50%)
抗生素活性譜
Gram-negative bacteria
Gram-positive bacteria
作用方式
cell wall synthesis | interferes
儲存溫度
-10 to -25°C
SMILES 字串
O=S([O-])(O)=O.OC(C1=C(C[N+]2=CC(NC(NCCN)=O)=C(N2C)N)CS[C@@]([C@@H]3NC(/C(C4=NSC(N)=N4)=N\OC(C)(C)C(O)=O)=O)([H])N1C3=O)=O
InChI
1S/C23H30N12O8S2.H2O4S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-5(2,3)4/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);(H2,1,2,3,4)/b31-11-;/t12-,18-;/m1./s1
InChI 密鑰
UJDQGRLTPBVSFN-TVNHLQOTSA-N
一般說明
Ceftolozane is a novel oxyimino-aminothiazolyl cephalosporin compound. It was formerly known as CXA-101 and FR264205. Ceftolozane is structurally similar to ceftazidime with an amino-thiadiazole ring on the 7-position side chain.
生化／生理作用
Ceftolozane is an antipseudomonal β-lactam inhibitor. It is also a PBP3 inhibitor with a higher affinity for PBP1b compared with other β-lactam inhibitors. Ceftolozane is stable in human plasma, but a low plasma protein binding (20%). It is primarily excreted through urine unchanged. Ceftolozane is a potent antibiotic against Gram-negative bacteria like P. aeruginosa, and Enterobacteriaceae.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination.
Mai-Chi Hong et al.
Infection and drug resistance, 6, 215-223 (2013-12-19)
The management of infections caused by multidrug-resistant Gram-negative bacteria, particularly Pseudomonas aeruginosa, continues to be a significant challenge to clinicians. Ceftolozane/tazobactam is a novel antibacterial and β-lactamase-inhibitor combination that has shown appreciable activity against wild-type Enterobacteriaceae and potent activity against
Fekade B Sime et al.
Antimicrobial agents and chemotherapy, 63(10) (2019-07-31)
Evaluation of dosing regimens for critically ill patients requires pharmacokinetic data in this population. This prospective observational study aimed to describe the population pharmacokinetics of unbound ceftolozane and tazobactam in critically ill patients without renal impairment and to assess the
Jens Martens-Lobenhoffer et al.
Journal of pharmacological and toxicological methods, 103, 106692-106692 (2020-03-17)
Ceftolozane is a newer β-lactam antibiotic drug effective against gram-negative pathogens. Its pharmacokinetic parameters are dominated by the patients' kidney function. Consequently, in patients with impaired kidney function or those who are treated with different forms of renal replacement therapy
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務